Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sisunatovir in pediatric RSV lower respiratory tract infection
NCT06102174Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Feb 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing Placebo with Sisunatovir (2 arms). Primary endpoints: Treatment Emergent Adverse Events at 33 days, Discontinuation From Study Due to Treatment Emergent Adverse Events at 33 days and 3 more. Started Feb 2024; status: terminated.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06102174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06102174.